Bath & Body Works' (BBWI) Q3 results "unexpectedly delivered topline upside on core product strength," Morgan Stanley said in a report emailed Tuesday.
The investment bank said it now has an "incremental conviction" in the company's "ability to deliver at least +LSD% steady-state growth over time -- a positive development following our more uncertain view exiting 2Q."
Even after Bath & Body Works' share price gains on Monday its "valuation remains inexpensive" which indicates "ongoing room for re-rating closer to peers with similar financial profiles," the report said.
The re-rating opportunity combined with "clear momentum/positive rate of change in topline growth trends" plus the company's "relative tariff insulation vs. peers" and "attractive relative position" warrants the continuation of its overweight rating, Morgan Stanley said.
The investment firm raised Bath & Body Works' price target to $49 from $48.
Price: 34.72, Change: -1.06, Percent Change: -2.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.